Estrella Immunopharma, Inc. (ESLA) Retained Earnings (Accumulated Deficit) USD 2021 - 2024

Historical data

Taxonomy & unit: us-gaap: USD
Description: The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary: Estrella Immunopharma, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from 2021 to 2024.
Estrella Immunopharma, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending March 31, 2024 was -$15.5 M, a 515% decline year-over-year.

Retained Earnings (Accumulated Deficit), Quarterly (USD)

Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q1 2024	-$15.5 M	-$13 M	-515%	Mar 31, 2024	10-Q	2024-05-15
Q4 2023	-$15.1 M	-$12.8 M	-568%	Dec 31, 2023	10-Q	2024-02-14
Q3 2023	-$14.1 M	-$12.1 M	-609%	Sep 30, 2023	10-Q	2023-11-20
Q2 2023	-$12.2 M	-$10.7 M	-709%	Jun 30, 2023	10-Q	2024-05-15
Q1 2023	-$2.53 M	-$1.38 M	-120%	Mar 31, 2023	10-Q	2023-05-18
Q4 2022	-$2.26 M	-$1.25 M	-124%	Dec 31, 2022	10-Q	2023-08-01
Q3 2022	-$1.98 M	-$1.11 M	-128%	Sep 30, 2022	10-Q	2022-11-14
Q2 2022	-$1.51 M	-$895 K	-146%	Jun 30, 2022	10-Q	2022-08-08
Q1 2022	-$1.15 M			Mar 31, 2022	10-Q	2022-05-16
Q4 2021	-$1.01 M			Dec 31, 2021	10-K	2023-03-14
Q3 2021	-$871 K			Sep 30, 2021	10-Q	2021-11-10
Q2 2021	-$612 K			Jul 19, 2021	10-Q	2021-11-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.